Incyte Signs a License Agreement with InnoCare to Develop and Commercialize Tafasitamab in Greater China
Shots:
- Incyte to receive $35M up front & is eligible to receive an additional ~$82.5M as development- regulatory & commercial milestones along with royalties. The collaboration will accelerate the development of tafasitama in China
- InnoCare to obtain rights to develop & exclusively commercialize tafasitamab in hematology & oncology in mainland China- Hong Kong- Macau & Taiwan
- Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting mAb. In Jun'21- EMA’s CHMP has issued a positive opinion recommending CMA of tafasitamab + lenalidomide for r/r DLBCL who are not eligible for ASCT while EC is currently reviewed CHMP opinion to grant marketing authorization in EU
Ref: Businesswire | Image: List23
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com